Most of the rest of the World is "minorities', non white. In the USA 35%+ suffering from effects of Covid are non/white. A large majority everywhere may not be able to purchase any Covid drug because of price and don't have healthcare and especially "Cadillac" policies.
In the USA we have some plans to distribute and pay for COVID medications and care. Other governments are doing their best, most better than here, I guess.
Aviptadil prices discussed here and from JJ will/May be 3X what a Remdesivir course costs and is probably/possibly worth much more, as Rem has a <20% benefit and early results for Aviptadil seem to indicate much better benefits, both as a Treatment and as a prophylactic.
BUT......
There IS a need to treat as many as possible both in the USA throughout it's whole populations and considerations for the rest of the world. I saw the 50-50% and 85-15% splits for IV(?**) which is about profits, but maybe I missed plans for distribution partners.
I saw/heard about work toward these goals but think announcing actual progress of plans or even Discussions with other Govs/Countries/Groups(!!) could support the pps for a better base, while we wait for the bigger news.
Inhaler products are the Golden ticket. That's why there are TWO trials planned for them, IMO. But...
I (We?) haven't seen the EUA and I Ass-ume it is for the IV.?**. Recruiting Trial in progress is IV.
Expanded access...
**Patients will be treated with 12 hour infusions of RLF-100 at ascending doses of 50/100/150 pmol/kg/hr on 3 successive days
